Scientific capability / Extracellular Lysosomal Degradation · ASGPR-LYTAC

Give an extracellular target a route to clearance.

Some disease targets sit outside the reach of intracellular degradation machinery. BioTwin’s ASGPR-LYTAC method composes a supplied target-binding ligand with GalNAc and a linker for a lysosomal-clearance hypothesis.

Current work Computational construct composition

Illustration of a lipid membrane, an embedded protein and nearby molecules.

Construct scenario

Turn a binder into a construct you can evaluate.

A team has an extracellular target binder and wants to explore receptor-mediated clearance. Consider a construct request with three GalNAc arms and a 20 Å linker span. The composition operation combines the supplied ligand with a span-selected PEG linker and GalNAc cluster, then requests structure verification and molecular descriptors. This makes the proposed construct specific enough to inspect and compare.

  1. Binder + 3 armsDefine the construct request

    Supply the targeting ligand and a 20 Å span to examine.

  2. Structure + descriptorsCheck the composition

    Return a valid molecular representation and computed descriptors when checks succeed. GalNAc stereochemistry and receptor recognition need their own checks.

  3. Binding → clearanceChoose the biological tests

    Check target binding, receptor-dependent uptake and lysosomal target loss.

Construct scenario based on a retained composition fixture. The fixture uses a placeholder fragment, not a validated target binder. No uptake, degradation or oral-exposure result is represented.
Explore the method and comparison sources
  • An informative failure is an output · If the structure is invalid or the descriptor engine is unavailable, the operation reports the failure instead of filling in molecular properties. A construct that cannot be verified should be resolved before comparing its delivery assumptions.
  • Compare the same therapeutic job · Published ASGPR-LYTACs already link target binders to GalNAc for degradation. For this candidate, compare the binder alone with the proposed conjugate, include receptor-dependence controls and test degradation separately from uptake. Computed size and polarity help frame those experiments; they do not establish clearance.

A construct you can interrogate

The design operation brings the targeting element, receptor-recruiting cluster and linker geometry into one candidate specification. Computed descriptors help examine the proposed construct. The biological question is whether target binding, receptor engagement, uptake and clearance cooperate in the intended setting.

ASGPR-targeting LYTACs are an established research approach. BioTwin’s current contribution is construct composition for a supplied targeting ligand, with the required biological tests kept distinct.

Start with a clearance mechanism that fits the target
QuestionFamiliar approachBioTwin focusPractical consequence
MechanismPublished ASGPR-LYTAC work uses target binding and a GalNAc-based receptor ligand to recruit lysosomal clearance.Compose the supplied targeting element, GalNAc cluster and a geometry-informed linker.Assess a concrete construct within a known mechanism.
Starting informationThe published approach requires a molecule that binds the extracellular target.The targeting ligand is an input to this operation.Binder discovery remains a separate job when no suitable ligand exists.
EvidencePublished examples include experimental target degradation.Current construct output provides a design and computed descriptors; uptake and clearance need testing.Plan assays for each missing step before interpreting target loss.

This is a comparison of scope and evidence. Each proposed construct needs its own evidence for target binding, uptake and clearance.

Where this can change the program

A team with a suitable extracellular binder can investigate clearance as a different therapeutic job from occupancy alone. The immediate output is a construct to evaluate. Target depletion, receptor dependence and the resulting functional effect remain separate experimental questions.

Check the bridge and the destination

Linker analysis and hepatic-targeting models offer adjacent questions about the construct and its route. A joint analysis must use compatible assumptions; availability of the individual methods does not establish a completed delivery workflow.

Further reading

Start with the binder and the clearance objective.

Describe the extracellular target, available targeting ligand and intended biological setting to scope a construct assessment.